Kaplan Fox Urges Investors of Medline Inc. (MDLN) with Losses to Contact the Firm
Newsfile Corp•02/10/2026•14:00 ET
3
Key Highlights
- ➤FDA warning cited significant Current Good Manufacturing Practice violations at Medline (MDLN)
- ➤Medline (MDLN) allegedly failed to thoroughly investigate unexplained discrepancies or batch failures
- ➤MDLN shares fell $2.56, or 7.16%, closing at $33.19 on June 2, 2026
- ➤Reuters said FDA action marked the second manufacturing-quality action against Medline in two months
New York, New York--(Newsfile Corp. - October 2, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN).
CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION
Get started
Create a free account to read the full story.